Boehringer Ingelheim’s Jascayd blocks a protein involved in the lung inflammation that develops from idiopathic pulmonary fibrosis, a rare and ultimately fatal disease with few available therapies. The twice-daily pill doesn’t cure IPF but clinical trial results showed it slowed disease progression.

MedCity News

08.10.2025

How Are Healthcare Leaders Tackling Automation Bias? - MedCity News

At MedCity News’ INVEST Digital Health conference, healthcare experts explored strategies to mitigate automation bias — emphasizing the importance of vendor responsibility, use case-specific governance and clinician engagement.

MedCity News

08.10.2025

The Future of AI in Healthcare Depends on Clinical Data Quality Assessment - MedCity News

Clinical Architecture Founder and CEO Charlie Harp talked about how clinical data can be assessed and improved to build trust from the healthcare industry.

MedCity News

08.10.2025

Turning Missed Appointments into Meaningful Member Action - MedCity News

Improving no-show rates is not just about perfecting our reminders — it’s about redesigning the member experience from the ground up and creating systems that reflect and accommodate the realities of members’ lives.

home›MedCity News

MedCity News

Health

Boehringer Ingelheim Drug Wins FDA Approval for Treating Fatal Lung Disorder IPF - MedCity News

How Are Healthcare Leaders Tackling Automation Bias? - MedCity News

The Future of AI in Healthcare Depends on Clinical Data Quality Assessment - MedCity News

Turning Missed Appointments into Meaningful Member Action - MedCity News

home
›
MedCity News